ARYx Therapeutics Inc: Company Strategy, SWOT Analysis and 5-year Adjusted Financials

Questions: Discounts, Updates etc.

Price: $495.00

Publication Date: 11-Jun-08

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

ARYx is a development-stage biopharmaceutical company that leverages its proprietary RetroMetabolic technology platform to design and develop commercially successful drugs by eliminating safety issues associated with those drugs. Its product pipeline includes three potential blockbusters: ATI-7505 for gastrointestinal disorders; ATI-5923 for blood thinning (anti-coagulant);


Scope

  • Contains corporate strategy, value chain presence and SWOT Analysis
  • Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors
  • Includes information on suppliers/ partners, shareholding structure and key employees with biographies


    • Report Highlights
    The company develops safer oral product candidates that retain the efficacy of commercially successful drugs for established chronic markets. The company employs its RetroMetabolic drug design technology to engineer structurally molecules. The process utilizes a series of steps designed to eliminate specific unwanted effects of the original drug.

    ARYx has only recognized revenues of $5 million in 2006 since its inception in 1997, under its collaboration agreement with Procter & Gamble (P&G) for the development and commercialization of ATI-7505.

    During the forecast period of 2006-2010, the company's total revenues are expected to increase at a CAGR of 45%, from $5 million to $21 million. It represents an absolute growth of +$15 million during the period, due to an increase in its license fee and collaboration revenues from its collaborative partner, P&G.


    Reasons to Purchase

  • Access all the important information and analysis on the company in a single report
  • Understand company's strengths, weaknesses, opportunities and threats along with business strategy and value chain
  • Gain access to company's adjusted five year financial data along with key ratios and market capitalization

    • Table of Contents

    Other users found this report page using the following search terms: swot pg analysis gamble procter ati aryx therapeutics company drug

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.


    Refund and Cancellation Policy: The descriptions of the products and services sold on LeadDiscovery.co.uk are as complete and accurate as possible, and customers are encouraged to read all available information about a product before placing an order. Due to the nature of the information being sold, orders for reports cannot be canceled.